Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPI-001 for Retinitis Pigmentosa in Usher Syndrome
NCT07710196Phase 3Recruiting
- Sponsor
- Nacuity Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 3 trial of N-acetylcysteine amide in retinitis pigmentosa (RP), sponsored by Nacuity Pharmaceuticals. Started Oct 2026; status: recruiting.
02
Drugs
N-acetylcysteine amide
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT07710196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710196.